surmount trial tirzepatide SURMOUNT-2: confers about 15% weight loss in adults with obesity and diabetes Surmount Press Briefing #ADA2022

Similarly, patients with obesity who stop losing weight may benefit from higher doses that further suppress appetite

My confidence is back, and so is my fun, silly personality

Furthermore, people with both type 2 diabetes and obesity who received a 15 mg dose of tirzepatide lost an average of 34.4 pounds (15.7 percent of their weight) after 72 weeks compared with 7 pounds lost (a 3.3 percent body weight loss) for the placebo group, according to a study published last month in The Lancet

And also you are not sitting there forever waiting like a normal Urgent care

We use structured weaning protocols to help you transition off while preserving results

These pharmacies measure and mix a drugs active ingredient, creating a product thats essentially a copy of the brand-name drug